
GLP-1 Diabetes Drugs Hint at Slowing Cancer Spread, Early Observational Findings
New findings from the Cleveland Clinic, presented at the ASCO meeting, suggest GLP-1 medications may be linked to reduced metastatic progression in several obesity-related cancers (notably non-small cell lung, breast, colorectal, and liver cancers) when compared with DPP-4 inhibitors. The study is observational and not peer‑reviewed, and it does not prove GLP-1s kill cancer cells or should be used for cancer prevention. Researchers caution that more rigorous, randomized trials are needed before changing cancer treatment guidelines.





